The U.S. FDA has recently given the green light to AstraZeneca Plc's Koselugo (selumetinib) granules and capsules for children aged 1 and above with neurofibromatosis type 1 (NF1) presenting symptomatic, inoperable plexiform neurofibromas (PN), which are benign nerve sheath tumors. NF1 is a genetic condition leading to the growth of non-cancerous tumors in the nervous system, skin, and bones. Back in 2020, selumetinib capsules were FDA-approved for pediatric patients aged 2 and older with NF1 exhibiting symptomatic, inoperable PN. The latest approval is founded on sufficient... More details accessible on Benzinga.com.